Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Xinxiang Medical College
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05319886CT.gov Observational Study of the Efficacy and Safety of Anlotinib Combined With Penpulimab in Elderly Lung Cancer Patients | — | Unknown | — | — | — |
NCT03780283CT.gov Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC | — | Unknown | — | — | — |
NCT03765775CT.gov Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative | — | Unknown | — | — | — |
NCT03589950CT.gov Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Catequentinib (this asset) | The First Affiliated Hospital of Xinxiang Medical College | P2 | CCC · 53 |
| Carboplatin | Nanfang Hospital, Southern Medical University | P4 | BB |
| Nivolumab | Hospital Israelita Albert Einstein | P2 | BB |
| Belagenpumatucel-L (Sk-Lu-1) | NovaRx Corporation | P3 | BB |
| Icotinib | Fuda Cancer Hospital, Guangzhou | P4 | BB |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | BB |
| Cyclophosphamide | Pfizer | P3 | BB |
| Rivoceranib | Fuzhou General Hospital | P3 | BB |
| Trastuzumab | Cancer Research UK | P2/3 | B |
+39 more in the Lung Neoplasm cohort
Other indications for Catequentinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Refractory Malignant Neoplasm | — | P3 | BB · 70 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BB · 66 |
| Kidney Cancer | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Catequentinib in Lung Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/catequentinib-lung-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →